Skip to main content
OpenTrials
Completed

NCT Number: NCT00186290

Allo BMT in Advanced Leukemia or High Grade Lymphoma

To evaluate the role of ablative allogeneic hematopoietic cell transplantation in the treatment of advanced leukemia or lymphoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lymphoma, Non-Hodgkin Blood and Marrow Transplant (BMT) Hematologic Diseases Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Leukemia Lymphatic Diseases Lymphoma Lymphomas: Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

Up to 50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Stanford University School of Medicine

Stanford, California, 94305, United States

About this study

To determine the disease free survival and overall survival of patients with ALL and ANLL after induction failure, in relapse, or subsequent remission from CML in several phases or recurrent lymphoblastic lymphoma who receive fractionated TBI, etoposide and cyclophosphamide followed by allogenic bone marrow grafting from histocompatible sibling donors. Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients with Advanced Leukemia or High Grade Lymphoma

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HLA identical donor

  • adequate organ function
  • other life threatening disease

Treatment and study plan

ablative allogeneic hematopoietic cell transplantation

Procedure

Primary outcomes

  1. overall survival

    Time frame: october 2009

  2. disease free survival

    Time frame: October 2009

Secondary outcomes

  1. early and late toxicities of the treatment regimen

    Time frame: October 2009

Sponsors and collaborators

Lead sponsor

Stanford University

Other

Registry information

Official study title

Fractionated Total Body Irradiation (FTBI), Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Allogeneic Bone Marrow Transplantation for Patients With Advanced Leukemia or High Grade Lymphoma

Important dates

Study start
1989
Primary completion
2009
Study completion
2009
First posted
Sep 16, 2005
Registry last updated
Oct 11, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.